Product Description
NIB101 is a CAR-T cell (chimeric antigen receptor-T cell) derived from autologous T cells equipped with PRIME technology and targets GM2, a type of glycolipid expressed on certain types of cancer cells. (Sourced from: https://www.noile-immune.com/dcms_media/other/20210914_Announcement_of_Clinical_Trial_Notification_submission_of_NIB101_en.pdf)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Autologous CAR-T
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Noile-Immune Biotech
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05192174 |
NIB101-01 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2025-05-16 |
12% |
2025-05-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|